Match!
Aaron K. Aragaki
Fred Hutchinson Cancer Research Center
Randomized controlled trialWomen's Health InitiativeBreast cancerDiabetes mellitusMedicine
157Publications
41H-index
10.9kCitations
What is this?
Publications 155
Newest
#1Rowan T. ChlebowskiH-Index: 79
#2Aaron K. AragakiH-Index: 41
Last. Ross L. PrenticeH-Index: 102
view all 3 authors...
Source
#1Ross L. Prentice (Fred Hutchinson Cancer Research Center)H-Index: 102
#2Aaron K. Aragaki (Fred Hutchinson Cancer Research Center)H-Index: 41
Last. Lihong Qi (UC Davis: University of California, Davis)H-Index: 25
view all 13 authors...
Source
#1Ross L. Prentice (Fred Hutchinson Cancer Research Center)H-Index: 102
#2Aaron K. Aragaki (Fred Hutchinson Cancer Research Center)H-Index: 41
Last. Lihong Qi (UC Davis: University of California, Davis)H-Index: 25
view all 13 authors...
Dual outcome intention-to-treat hazard rate analyses have potential to complement single outcome analyses for the evaluation of treatments or exposures in relation to multivariate time-to-response outcomes. Here we consider pairs formed from important clinical outcomes for further insight into menopausal hormone therapy influences on chronic disease. The Women's Health Initiative randomized, placebo controlled, hormone therapy trials (1993 to present, at 40 U.S. clinical centers) of conjugated e...
Source
#1Kerryn W. Reding (UW: University of Washington)H-Index: 11
#2Aaron K. Aragaki (Fred Hutchinson Cancer Research Center)H-Index: 41
Last. Mara Z. Vitolins (Wake Forest University)H-Index: 48
view all 20 authors...
BACKGROUND: Recent clinical trials have evaluated angiotensin-converting enzyme (ACE) inhibitors (ACEis), angiotensin receptor blockers (ARBs), and beta blockers (BBs) in relation to cardiotoxicity in patients with cancer, typically defined by ejection fraction declines. However, these trials have not examined long-term, hard clinical endpoints. Within a prospective study, we examined the risk of heart failure (HF) and coronary heart disease (CHD) events in relation to use of commonly used antih...
Source
#1Rowan T. Chlebowski (UCLA Medical Center)H-Index: 79
#2Aaron K. Aragaki (Fred Hutchinson Cancer Research Center)H-Index: 41
Last. Ross L. Prentice (Fred Hutchinson Cancer Research Center)H-Index: 102
view all 4 authors...
After reports from the Women's Health Initiative randomized trial evaluating estrogen plus progestin, there was a sudden, substantial, and sustained decrease in all categories of menopausal hormone therapy, and the first reduction in age-adjusted breast cancer incidence in more than 20 years was seen in 2003-2004 among US women 50 years of age or older. Subsequent trends in breast cancer incidence have been described, but most reports have not focused on the postmenopausal age group or fully eng...
Source
#1Rowan T. ChlebowskiH-Index: 79
Last. Dorothy S. LaneH-Index: 46
view all 17 authors...
2 CitationsSource
#1Linda Van Horn (NU: Northwestern University)H-Index: 75
#2Aaron K. Aragaki (Fred Hutchinson Cancer Research Center)H-Index: 41
Last. Mara Z Vitolin (Wake Forest University)H-Index: 1
view all 13 authors...
Background: Women without cardiovascular disease (CVD) or hypertension at baseline assigned to intervention in the Women's Health Initiative Dietary Modification (DM) trial experienced 30% lower risk of coronary heart disease (CHD), whereas results in women with hypertension or prior CVD could have been confounded by postrandomization use of statins. Objectives: Intervention participants reported various self-selected changes to achieve the 20% total fat goals. Reviewed are intervention compared...
1 CitationsSource
#1Rowan T. Chlebowski (Los Angeles Biomedical Research Institute)H-Index: 79
#2Aaron K. Aragaki (Fred Hutchinson Cancer Research Center)H-Index: 41
Last. Karen C. Johnson (UTHSC: University of Tennessee Health Science Center)H-Index: 69
view all 16 authors...
PURPOSEObservational studies of dietary fat intake and breast cancer have reported inconsistent findings. This topic was addressed in additional analyses of the Women’s Health Initiative (WHI) Diet...
3 CitationsSource
#1Kathy Pan (Los Angeles Biomedical Research Institute)H-Index: 7
#2Rebecca A. Nelson (City of Hope National Medical Center)H-Index: 29
Last. Rowan T. Chlebowski (City of Hope National Medical Center)H-Index: 79
view all 16 authors...
BACKGROUND: Insulin resistance has been proposed as a mediator of the increased cancer incidence and mortality associated with obesity. However, prior studies included limited cancer deaths and had inconsistent findings. Therefore, we evaluated insulin resistance and cancer-specific and all-cause mortality in postmenopausal women participating in the Women's Health Initiative (WHI). METHODS: Eligible were a subsample of 22 837 WHI participants aged 50-79 years enrolled at 40 US clinical centers ...
1 CitationsSource
#1Rowan T. Chlebowski (UCLA: University of California, Los Angeles)H-Index: 79
#2Steve Rapp (Wake Forest University)H-Index: 3
Last. Ross L. Prentice (Wake Forest University)H-Index: 1
view all 15 authors...
Abstract Background Meta-analyses of observational studies associate adherence to several dietary patterns with cognitive health. However, limited evidence from full scale, randomized controlled trials precludes causal inference regarding dietary effects on cognitive function. Methods The Women's Health Initiative (WHI) Dietary Modification (DM) randomized trial, in 48,835 postmenopausal women, included a subset of 1,606 WHI Memory Study (WHIMS) participants >= 65 years old, to assess low-fat di...
1 CitationsSource
12345678910